BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3089% below fair value
$0.77−0.05 (-6.56%)
Close on Nov 17, 2026Market cap $2.25MP/E –Yield –
BioNexus Gene Lab total assets
Total assets on the balance sheet at the end of each period.
BioNexus Gene Lab's total assets was $8.73M at Jun 30, 2026. For fiscal 2025 it was $9.25M, down 11.3% from the year before. The highest annual figure on record is $11.40M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.25M | -11.3% |
| FY2024 | Dec 31, 2024 | $10.43M | -8.5% |
| FY2023 | Dec 31, 2023 | $11.40M | +30.4% |
| FY2022 | Dec 31, 2022 | $8.74M | -8.7% |
| FY2021 | Dec 31, 2021 | $9.57M | -5.3% |
| FY2020 | Dec 31, 2020 | $10.12M | +721.6% |
| FY2019 | Dec 31, 2019 | $1.23M | -25.5% |
| FY2018 | Dec 31, 2018 | $1.65M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $8.73M | -7.4% |
| Q1 FY2026 | Mar 31, 2026 | $9.04M | -4.6% |
| Q4 FY2025 | Dec 31, 2025 | $9.25M | -11.3% |
| Q3 FY2025 | Sep 30, 2025 | $7.62M | -30.7% |
| Q2 FY2025 | Jun 30, 2025 | $9.42M | -15.4% |
| Q1 FY2025 | Mar 31, 2025 | $9.48M | -15.1% |
| Q4 FY2024 | Dec 31, 2024 | $10.43M | -8.5% |
| Q3 FY2024 | Sep 30, 2024 | $11.00M | -4.1% |
| Q2 FY2024 | Jun 30, 2024 | $11.14M | +41.0% |
| Q1 FY2024 | Mar 31, 2024 | $11.16M | +36.3% |
| Q4 FY2023 | Dec 31, 2023 | $11.40M | +30.4% |
| Q3 FY2023 | Sep 30, 2023 | $11.47M | +47.0% |
| Q2 FY2023 | Jun 30, 2023 | $7.90M | -5.6% |
| Q1 FY2023 | Mar 31, 2023 | $8.19M | -10.8% |
| Q4 FY2022 | Dec 31, 2022 | $8.74M | -8.7% |
| Q3 FY2022 | Sep 30, 2022 | $7.80M | -20.1% |
| Q2 FY2022 | Jun 30, 2022 | $8.37M | -11.4% |
| Q1 FY2022 | Mar 31, 2022 | $9.18M | -7.3% |
| Q4 FY2021 | Dec 31, 2021 | $9.57M | -5.3% |
| Q3 FY2021 | Sep 30, 2021 | $9.77M | +863.8% |
| Q2 FY2021 | Jun 30, 2021 | $9.45M | +791.1% |
| Q1 FY2021 | Mar 31, 2021 | $9.90M | +778.4% |
| Q4 FY2020 | Dec 31, 2020 | $10.12M | +721.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.01M | -24.6% |
| Q2 FY2020 | Jun 30, 2020 | $1.06M | -29.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.13M | -29.9% |
| Q4 FY2019 | Dec 31, 2019 | $1.23M | -25.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.34M | – |
| Q2 FY2019 | Jun 30, 2019 | $1.51M | – |
| Q1 FY2019 | Mar 31, 2019 | $1.61M | – |
| Q4 FY2018 | Dec 31, 2018 | $1.65M | – |
See a number that looks wrong?